VIDEO: Combination therapies showing promise in metastatic triple-negative breast cancer

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

So, although combination chemotherapies is not something that we do that often in metastatic triple-negative breast cancers, there actually are some interesting laboratory data which suggests some potential synergies. I would say the most promising combination of therapy right now that's being evaluated in clinical trials is one looking at datopotamab deruxtecan, which is an antibody drug conjugate. It's a TROP2 antibody with the deruxtecan payload combined, and then that's combined with durvalumab. In the early Phase 1/2 BEGONIA trial that was presented at ESMO in 2023, there was actually a very impressive overall response rate of 79% for the combination in metastatic triple-negative breast cancers. So as you can imagine, this is something that we'll be moving forward for further evaluation. As a side note, datopotamab also appears to have activity for hormone receptor positive cancers as well. Another interesting combination, which actually has very compelling laboratory activity, which is a combination of PARP inhibitors and immunotherapy, with the idea that PARP inhibitors could somehow prime the cells to respond to immunotherapy. And as I said, in vitro data have been very promising. This is a situation, however, that the laboratory data definitely show that the combination is safe, so you can give immunotherapy in combination with a PARP inhibitor. So for instance, in someone being treated in the adjuvant setting with a residual disease as a germline BRCA1/2 mutation carrier. However, the limited clinical data that's been presented has not clearly yet shown synergy in humans. But I would still say that based upon the laboratory evidence, this is definitely still an area that there are going to be some continued clinical trials evaluating this combination.